Bio-Techne (TECH) to Release Quarterly Earnings on Wednesday

Bio-Techne (NASDAQ:TECH) is expected to issue its Q2 2026 results before the market opens on Wednesday, February 4th. Analysts expect Bio-Techne to post earnings of $0.43 per share and revenue of $290.2040 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 9:00 AM ET.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $0.42 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.42. The business had revenue of $286.56 million for the quarter, compared to analysts’ expectations of $292.02 million. Bio-Techne had a net margin of 6.41% and a return on equity of 13.59%. The business’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.42 EPS. On average, analysts expect Bio-Techne to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Bio-Techne Stock Up 1.8%

Shares of NASDAQ TECH opened at $65.25 on Tuesday. The company has a quick ratio of 2.81, a current ratio of 4.22 and a debt-to-equity ratio of 0.15. Bio-Techne has a 52 week low of $46.01 and a 52 week high of $79.28. The firm has a 50-day moving average price of $63.17 and a 200 day moving average price of $59.05. The stock has a market capitalization of $10.17 billion, a price-to-earnings ratio of 133.17, a price-to-earnings-growth ratio of 4.42 and a beta of 1.48.

Bio-Techne Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, November 28th. Stockholders of record on Monday, November 17th were given a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, November 17th. Bio-Techne’s dividend payout ratio (DPR) is presently 65.31%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TECH. UBS Group upped their price target on Bio-Techne from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, November 6th. Deutsche Bank Aktiengesellschaft set a $72.00 target price on Bio-Techne and gave the company a “buy” rating in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bio-Techne in a research note on Wednesday, January 21st. Evercore ISI set a $62.00 price objective on shares of Bio-Techne and gave the stock an “in-line” rating in a research report on Monday, January 5th. Finally, Zacks Research downgraded shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Bio-Techne presently has an average rating of “Moderate Buy” and an average price target of $70.57.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wellington Management Group LLP raised its stake in Bio-Techne by 349.8% during the third quarter. Wellington Management Group LLP now owns 5,115,133 shares of the biotechnology company’s stock worth $284,555,000 after purchasing an additional 3,978,026 shares during the period. Invesco Ltd. increased its holdings in shares of Bio-Techne by 7.7% during the 3rd quarter. Invesco Ltd. now owns 3,946,028 shares of the biotechnology company’s stock worth $219,518,000 after buying an additional 283,303 shares during the last quarter. DF Dent & Co. Inc. raised its position in shares of Bio-Techne by 2.1% in the 3rd quarter. DF Dent & Co. Inc. now owns 2,780,961 shares of the biotechnology company’s stock worth $154,705,000 after buying an additional 56,219 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Bio-Techne by 3.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,710,513 shares of the biotechnology company’s stock valued at $95,129,000 after acquiring an additional 49,172 shares during the last quarter. Finally, UBS Group AG grew its position in Bio-Techne by 52.1% during the third quarter. UBS Group AG now owns 1,509,436 shares of the biotechnology company’s stock valued at $83,970,000 after acquiring an additional 517,050 shares during the period. 98.95% of the stock is currently owned by hedge funds and other institutional investors.

About Bio-Techne

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.